以肿瘤低氧为靶点的生物还原剂的研究进展  

Recent advances in the study of bioreductive drugs targeted tumor hypoxia

作　　者：刘井宝[1] 傅磊[1] 胡永洲[2] 姜发琴[1] 

机构地区：[1]上海交通大学药学院药物化学教研室,上海200240 [2]浙江大学药学院药物化学教研室,浙江杭州310058

出　　处：《药学学报》2009年第7期695-702,共8页Acta Pharmaceutica Sinica

摘　　要：肿瘤低氧是实体瘤发展过程中必经的过程,是引起肿瘤耐药、复发、侵袭和转移的重要原因。低氧肿瘤细胞对放疗化疗有一定的耐受。肿瘤低氧已成为肿瘤药物治疗的一个重要靶点,近年来,以肿瘤低氧为靶点的生物还原剂在治疗肿瘤方面取得了很大的进展。本文对生物还原剂研究的最新进展予以综述。Tumor hypoxia is the necessary process in the development of solid tumors, which is the key factor for drug resistance, recurrence, attack and shift of tumor. Hypoxic tumor cells have a certain extent of tolerance to radiation and chemotherapy. Tumor hypoxia is an important target for medication therapy. In the recent years, the bioreductive drugs targeted tumor hypoxia has made great process in the treatment of tumors. The latest advances of bioreductive drugs targeted hypoxia were reviewed in this paper.

关 键 词：低氧 肿瘤 生物还原剂 

分 类 号：R916[医药卫生—药学]